Extrapolating human toxicity data with target organ dose (TOD-Wb) model: A meso-scale allometric analytical approach

Swee-Cheng FOO*, Ivan Siang-Meng SIN, Hui-Fang ANG and Rachel Qian-Yun CHE

Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore.

Received 28 December, 2016; Accepted 24 July, 2017

An allometric target organ dose model (TOD-Wb) with variable scaling exponent, $b = br + bo(bm) - bi$, is proposed for the extrapolation of animal toxicity to human. The exponent $b$ comprises four constituent parameters representing the intake mode to entry organ ($bi$), route of transportation to target organ ($br$), mass of target organ ($bo$), and rate of metabolism at target organ ($bm$). This expression enables the a priori determination of $b$ from known values of $bi$, $br$, $bo$, and $bm$. From niprotilol that target the respiratory system, the $br$ values determined for intragastric (ig), intraperitoneal (ip), intravenous (iv), and subcutaneous (sc) injections were 0.15, 0.26, 0.03, and 0.61, respectively; from HF mouth breathing data, the $br$ value is 0.07 for pulmonary absorption through inhalation (ih); and from actinomycin D data that target bone marrow through the ip-route, the $bo$ value is 0.53. The model is tested with the parameter values obtained from literature; validating the a priori values determined in this paper with the empirical values measured. For ip-administration of OMPA and parathion, the a priori [3/4(bo) - 1] value and empirical value are -0.475 and -0.48; for nine alkylating agents, the values are -0.60 and -0.61; for ig-administration of NaCN, the [br + 3/4(bo) - 1] and empirical values are -0.1 and -0.092, respectively. The analysis of toxic gas inhalation data in student projects are also summarized herein. Consequently, values of these parameters can also be estimated by fitting known toxicity data to the TOD-Wb model.

Key words: Target organ dose model, allometric scaling, extrapolating human toxicity.

INTRODUCTION

Dose-response remains fundamental to quantitative assessment of human toxicity. The ability to identify toxicologically equivalent doses for human from different animal species is a challenge and the use of animal toxicity data sets remain essential to interspecies scaling. The two main current approaches to extrapolation of animal toxicity to human using (1) physiologically based pharmacokinetic (PBPK) model and (2) constant exponent allometric (Wb) model have been well recognized and applied.

The micro-scale PBPK model is knowledge and computation intensive, requiring detailed physiological...
and chemical reaction parameters for computer simulation. This mathematical intensive technique predicts the absorption, distribution, metabolism and excretion of the toxicant through the classical or physiological approach. The classical approach utilizes a lump-compartmental system and fits exponential functions to time-dependent plasma concentration data; while the physiological approach separates the body into a number of interconnected anatomical compartments through the body fluid systems (Gerlowski and Jain, 1983). However, this model is very time-consuming due to large number of parameters; which can be limiting due to parameter identify-ability and redundancy as some of these parameters may be correlated. For the macro-scale constant exponent ($W^6$) model, there are currently three proponents, each using the allometric scaling according to: (1) body surface area ($W^{2.3}$) or (2) physiological-time ($W^{3.4}$) or (3) body mass ($W^1$). The use of body surface area criterion has been a long established principle for extrapolating physiological or biological parameters, calculating drug dosages in human; using $b = 2/3$ power rule of the organisms’ body weight, a common practice in medical fields (Crawford et al., 1950; Talboy et al., 1953; Prenkel, 1958). This principle was first confirmed empirically with toxicity data of 18 anticancer drugs by Freireich et al. (1966) and evaluated further by Schein et al. (1970). Subsequently, interspecies metabolic rates, cardiac outputs, and ventilation rates were found to have a mass exponent of ¾ (Brody, 1945; Kleiber, 1947; Adolph, 1949; Stahl, 1967; Mcmahon, 1973; Lindstedt and Calder, 1981; Feldman and Mcmahon, 1983). The support for physiological-time scaling, $b = 3/4$ power rule (Travis and White, 1988) came about after reanalysis of Freireich et al. (1966) and Schein et al. (1970) toxicity data sets and the difference was recognized and attributed to surface area scaling being valid for intraspecies extrapolation; while physiological-time scaling being applicable to interspecies extrapolation. Most recently, publications have revised the support for the body mass scaling, with $b = 1$ power rule; either using the toxicity data in birds (Mineau et al., 1996) and reanalyzing Freireich’s data by taking the ratios of toxicity data of difference species with different body mass (Rhomberg and Wolff, 1998; Burzala-Kowalczyk and Jongblond, 2011). However, this constant exponent model ($W^6$) with $b = 2/3, 3/4$ or 1, does not explain nor reflect the varying exponent values exhibited. It does not take into account the constituent factors when (1) a specific toxicant is administered through different routes of entry and (2) when different chemicals are administered through the same route. To extrapolate human toxicity data without the PBPK parameter intensity and be able to better explain the constituent factors which the constant exponent ($W^6$) model did not reflect, an allometric model that incorporates the constituent factors from the route of administration, transport, and the eventual target organ metabolism of the toxicant would better explain the observed variance. This paper discusses the development of the meso-scale Target Organ Dose allometric scaling model (TOD-$W^{6b}$), incorporating the constituent factors of (1) intake mode ($bi$); (2) transport route ($br$); (3) target organ mass ($bo$); and (4) target organ metabolism ($bm$) into the exponent $b$ to enable its a priori determination. This target organ dose model (TOD-$W^{6b}$) will serve as a meso-scale model that lie in between the macro-scale constant exponent ($W^6$) and the micro-scale PBPK models. The model is also tested with some available toxicity data from literature.

**METHODOLOGY**

An allometric target organ dose model (TOD-$W^{6b}$) with variable scaling exponent, $b = bi + bo(bm)$ - $bi$, is developed and proposed as a meso-scale model for the extrapolation of animal toxicity to human. The exponent $b$ comprises four constituent parameters representing the intake mode through entry organ ($bi$), route of transportation to target organ ($br$), mass of target organ ($bo$), and rate of metabolism at target organ ($bm$). This expression enables the a priori determination of $b$ from known values of $bi$, $br$, $bo$, and $bm$.

Fundamentally, when a toxicant is introduced into a species’ body, the absorbed amount (internal dose), $m_a$ (mg) is the available dose to be transported to the eventual target organ. This amount is found to be directly proportional to the body weight, $W$ (kg) of the species raised to the mass scaling exponent, $b$:

$$m_a \propto W^b,$$

When $m_a$ results in 50% lethality, the expression can be written in exposure dose $LD_{50}$ ($kW^b$) as:

$$LD_{50} (kW^b) \propto W^b,$$

Where, $LD_{50}$ is the median lethal dose. This is the well-recognized and most commonly used allometric scaling rule on the correlation of physiological parameters or biological responses with a nonlinear function of body weight. The expression can be rewritten as:

$$LD_{50} (W^b) = KW^b,$$

Where, $K$ is the overall potency constant (chemical availability and efficacy) associated to the specific toxicant, proportional to its component intake-constant $k_i$, route-constant $k_r$, and metabolism-constant $k_m$ as the toxicant travel through its interaction pathway.

Based on the fundamental allometric rule, the effective target organ dose, TOD-$W^b$ is proportional to the mass of toxicant (m) absorbed and transported to the target organ divided by the weight of the target organ, $W_o$; raised to the metabolism-exponent, $bm$ at the target organ. Equation 2 can be rewritten as:

$$LD_{50} (W^b) \propto W_{o}^{bm},$$

Since the weight of the target organ $W_o$ is proportional to the species’ weight $W^{bo}$, where $bo$ is the exponent for the target organ, the expression can be written as:

$$W_o \propto W^{bo},$$

and substituting Equation 5 into Equation 4, gives Equation 6

$$LD_{50} (kW^b) \propto W^{bo(bm)},$$
Considering the transport route before the effective dose reaches to the target organ, the effective target organ dose is

$$LD_{50}(kW^i)/W^{br} = k_{km}W^{bo(bm)}$$,  

Rearranging Equation 7 gives the following expressions:

$$LD_{50} (kW^i) = k_{km}W^{br+bo(bm)}$$,  

$$LD_{50} = [(k_{km})W^{br+bo(bm)}]/(kW^i)$$,  

$$LD_{50} = KW^{br+bo(bm)-bi}$$  

Comparing Equations 3 and 10, exponent $b$ can be expressed in its constituent parameters as $br + bo(bm) - bi$; and we believed this expression would better reflect the variance observed as compared to being taken as a mere constant.

RESULTS

To ascertain whether the TOD-W$^b$ model is able to explain the variation observed in the measured values, it is applied to literature toxicity data by comparing the empirical-$b$ values to the $a$ priori-$b$ values determined with the model; which uses known values of $bi$, $br$, $bo$, and $bm$ obtained from literature or estimated using toxicity data. Since toxicity data is traditionally reported in mg per kg of body mass, Equation 10 can be expressed as:

$$LD_{50}/W = KW^{br+bo(bm)-bi-1}$$  

and using available toxicity data sets, the model can be tested and validated using the following:

(1) Plotting Log($LD_{50}/W$) against Log(W) for a specific toxicant administered through various entry-routes to give a series of lines each representing the potency of the toxicant to the target organ with respect to different entry-route and transport-route in relation to the body mass. Using Microsoft Excel, the empirical-$b$ values for each different route of entry and transport can be determined from the respective slopes [slope = $br + bo(bm) - bi - 1$] and compared to the $a$ priori-$b$ values determined from the model. Such an analysis is as shown in Figure 1. This is the simplest method and if the number of toxicity data points in each route is small or limited, the accuracy of the analysis can be improved by the use of advanced statistical methodology such as the General Linear Model (GLM). The use of method 2 is recommended.

(2) Plotting Log($LD_{50}/W/W^{br}$) against Log(W) for a specific toxicant administered through various entry-routes with corrected transport-route influence to give a series of parallel lines each representing the potency of the toxicant to the target organ with respect to different entry-route in relation to body mass. Using the GLM methodology, the empirical-$b$ values for each specific entry-route can be determined from the respective slopes [slope = $bo(bm) - bi - 1$] using analysis of covariance (ANCOVA) and compared to $a$ priori-$b$ values determined from the model. Such a plot is as shown in Figure 2. For this method, the plot can be cluttered with many lines when the analysis involves a large number of chemicals and routes; in this case, method 3 should be employed to collapse all the lines together into a one-line plot.

(3) Plotting Log($LD_{50}/W/W^{br}/K$) against Log(W) for a specific toxicant administered through various entry-routes with corrected transport-route influence and potency to give a single line representing the potency of
(4) the toxicant to the target organ regardless of entry-routes in relation to body mass. Using Microsoft Excel, the empirical-b values for a specific toxicant can be determined from the common slope \([\text{slope} = \text{bo} - \text{bi} - 1]\) and compared to the \textit{a priori}-b value determined from the model. Such a plot is as shown in Figure 3. This is the preferred and most efficient method to analyze multi-chemicals and multi-routes data sets that has the same target organ.

To test and validate the TOD-\(W^b\) model, parameter values for bi, bm, bo, and br are needed. For parameter values that are not found in literature, they are estimated by fitting appropriate toxicity data to the TOD-\(W^b\) model.

**Constituent parameter values**

Generally, two types of dose administration are carried out in toxicity testing; the forced-intake and \textit{ad libitum} methods. For forced intake (such as intragastric, intramuscular, intraperitoneal, intravenous, or subcutaneous injections), \(W^b = 1\) and \(bi = 0\) as the full dose of test toxicant is being delivered to the entry site without any losses. The most common forced-intake method is the bolus injection in which a volume of the test toxicant is delivered onto the chosen entry site within a short duration. For \textit{ad libitum} method, the bi values through food intake (Hart et al., 2002) is 2/3 for birds, 0.72 for mammals and through inhalation (Guyton, 1947a) is 3/4 for both birds and mammals. And given that bm = 3/4 has been well evaluated and accepted for the rate of metabolism (Kleiber, 1947), this value is also adopted for the model.

When the required parameter values are not available, appropriate toxicity data such as that of nipradilol are used to estimate the br values for intravenous (iv), subcutaneous (sc), intragastric (ig), and intraperitoneal
Table 1. Parameter br values for entry-route to target organ.

| Entry-route       | br Value | Chemical   | Source       |
|-------------------|----------|------------|--------------|
| Intragastric      | 0.15     | Nipradilol | This paper   |
| Intraperitoneal   | 0.26     | Nipradilol | This paper   |
| Intravenous       | 0.03     | Nipradilol | This paper   |
| Subcutaneous      | 0.61     | Nipradilol | This paper   |
| Nasal-larynx      | 1/3      | Aerosol    | Guyton, 1947 |
| Pulmonary (alveolus) | 0.07   | HF, mouth breathing | Lim, 2012 |

Table 2. Exponent value for organs.

| Organ                  | Mammals                   | Birds                   |
|------------------------|----------------------------|-------------------------|
| Brain                  | 0.70 (Brody, 1945; Adolph, 1949) | 0.50 (Brody, 1945)     |
| Pituitary              | 0.76 (Brody, 1945; Adolph, 1949) | -                       |
| Thyroids               | 0.80 (Brody, 1945; Adolph, 1949) | 0.86 (Brody, 1945)     |
| Kidney                 | 0.85 (Brody, 1945; Adolph, 1949) | 0.85 (Brody, 1945)     |
| Liver                  | 0.87 (Brody, 1945; Adolph, 1949) | 0.88 (Brody, 1945)     |
| Adrenals               | 0.92 (Brody, 1945; Adolph, 1949) | 0.89 (Brody, 1945)     |
| Stomach & intestines   | 0.94 (Brody, 1945; Adolph, 1949) | 0.92 (Brody, 1945)     |
| Heart                  | 0.98 (Brody, 1945; Adolph, 1949) | 0.92 (Brody, 1945)     |
| Lungs                  | 0.99 (Brody, 1945; Adolph, 1949) | 0.94 (Brody, 1945)     |
| Blood                  | 0.99 (Brody, 1945; Adolph, 1949) | -                       |
| Bone marrow            | 0.53, this paper            | -                       |

(ip) injections, and the actinomycin D toxicity data set is used to determine the bo value for bone marrow.

Analysis of nipradilol toxicity data for br values

Nipradilol toxicity data (Okudo et al., 1985) is analyzed with the TOD-W^br model to determine the br values for intravenous, intraperitoneal, intragastric, and subcutaneous injections by plotting the dosage LD_50/W (mg/kg) against the body mass (kg) in a log-log plot (Figure 1). The target organ is reported as the lungs (Okudo et al., 1985) with bo = 0.99 (Brody, 1945; Adolph, 1949); and by setting the exponent value, b = (3/4)bo - 1 as the slope of the regression line, the bo values of the target organ, regardless of the transport-route, can be calculated. For example, bo for the ig-route is b = (3/4)bo - 1 = -0.599; therefore, the estimated bo = [-0.599 + 1] (4/3) = 0.53.

The bo values determined in this paper and those from literature are shown in Table 2 as the following.

Model testing with toxicity data

The model is tested with toxicity data of two organophosphates in laboratory mammals, sodium cyanide (NaCN) in birds and nine alkylating anticancer agents in mice and rats.

Testing the model with toxicity data of two organophosphates

The toxicity data for OMPA (DuBois et al., 1950) and parathion (DuBois et al., 1949) through the ip-route are
tested against the model together, taking advantage of the same target organ (nervous system) and the structure of the model. The transport-route and potency adjusted variable, LD$_{50}$/W/W$^{br}$/K (mg/kg) is plotted against body mass (kg) in a log-log plot (Figure 3). The best fitted line gives the empirical-b of slope -0.480 as compared to the model's slope, $a$ priori-b = 3/4$bo$ - 1 = -0.475 (brain $bo$ = 0.7).

### Testing the model with toxicity data of sodium cyanide

Testing the model with the toxicity date of oral NaCN in birds (Wiemeyer et al., 1986) gives an empirical-b of -0.092 (Figure 4). With cyanide affecting all cells, $bo$ = 1 and oral ig-br = 0.15; the model determines the $a$ priori-b = br + (3/4)$bo$ - 1 = -0.1.

### Testing the model with toxicity data of nine alkylating anticancer agents

The toxicity data of nine alkylating agents (Philips and Thiersch, 1950) on mice and rats is used in this analysis. The chemicals were administered by one single ip-injection. The LD$_{50}$/W/W$^{br}$/K is plotted against W in a log-log plot (Figure 5) and the slope was obtained by the regression analysis, empirical-b = -0.61. The model' slope, $a$ priori-b = (3/4)$bo$ - 1 = -0.60 (bone marrow $bo$ = 0.53 from actinimycin D toxicity data analyzed in 3.1.2).

### Model testing results

In additional to the toxicity data sets used to test and validate the model in this paper, six nerve gas agents, two hydrazines, two mineral acids, three hypoxic gases,
and two corrosive gases were analyzed by students; the overall results are summarized subsequently (Table 3).

**DISCUSSION**

From the test, it was observed that the model a priori-b determined is congruous to the empirical-b from the measured toxicity data and is able to fully explain the observed variance when used to analyze toxicity data of systemic and local effects, including chemicals toxic to the respiratory, alkylating agents, hypoxic chemicals, nerve agents, renal toxic chemicals, irritating, and corrosive chemicals.

Studies also showed that the br value appears to be constant for a specific route indicating that there is a base-br value for each entry-route. The actual br value would be higher than the base-br value when there is a chemical-route specific interaction present. This behavior has been observed in some chemical toxicity studies (Sato and Nakajima, 1978; Jadhav et al., 2007). Hence, the current model needs further development to account for the following situations.

**The presence of specific chemical-route interaction along the path from the entry-site to the target organ**

Any departure from the expected pattern may signal the occurrence of specific chemical-route interaction along the path. Physiological and pathological studies should be carried out to clarify the possible chemical-route behavior in the test system. For examples, nasal deposition may cause local, systemic or direct effects to the brain via the olfactory region that by-passing the blood-brain barrier or the first-pass effect through the liver in the oral route (Jadhav et al., 2007).

The experimental b values for the iv route involving four chemicals are used to illustrate the differences in the slopes of LD/W against W plots as compared to those obtained from the fixed exponent model (slope = b -1) or from the TOD-Wb model (slope = br + bm(b0) + bi -1). For the iv to gastro-intestine route, the experimental slope values are -0.343 in the LD10 data and -0.347 for the LD50 for epi-doxorubicin; and -0.211 and -0.260 for doxorubicin, respectively (Bertazzoli, 1985) as compared to -0.265 in the TOD-Wb model. For the slope values involving iv to bone marrow, they are -0.533 for SOA (Nakano et al., 1984) and -0.479 for dolastatin-10 (Mirsalis et al., 1999) as compared to -0.565 in the TOD-Wb model. These slope values in the fixed exponent model are -1/3 (b = 2/3), -1/4 (b = 3/4) or 0 (b = 1) model. The 2/3 model appears to fit the epi-doxorubicin data; the 3/4 model fits the doxorubicin data. The TOD-Wb model explains all the data well.

**The involvement of multiple organs in the toxic effects**

In this situation, the current single target organ model could not be directly applicable. When multiple target organs are involved, the contribution of the secondary target organs to the overall bo value or the toxicity outcome has to be further modeled.

Future studies would be focused on by further validating the TOD-Wb model and re-analyzing published datasets. It is noteworthy that the same set of anticancer agents toxicity data used to established the 2/3 rule had also demonstrated the support for the 3/4 and unity rule

Table 3. Summary of TOD-Wb model testing.

| Chemical      | bo | Entry route | Empirical slope value | Model expression and a priori slope value | Source          |
|---------------|----|-------------|-----------------------|------------------------------------------|-----------------|
| OMPA          | 0.7| ip          | -0.480                | (¾)bo -1 = -0.475                        | This paper      |
| Parathion     | 0.7| ip          | -0.480                | (¾)bo -1 = -0.475                        | This paper      |
| NaCN          | 1.00| ig         | -0.092                | br+(3/4)bo-1 = -0.100                     | This paper      |
| Alkylating agents | 0.53| ip        | -0.61                 | (¾)bo -1 = -0.60                         | This paper      |
| HF, nose breathing | 0.99| ih        | 0.28                  | br+(3/4)bo-3/4 = 0.33                     | Lim, 2012       |
| HF, mouth breathing | 0.99| ih       | -0.0076               | (3/4)bo-3/4 = -0.0075                     | Lim, 2012       |
| HCl           | 0.99| ih          | 0.33                  | br+(3/4)bo-3/4 = 0.33                     | Lim, 2012       |
| Cl₂           | 0.99| ih          | 0.34                  | br+(3/4)bo-3/4 = 0.33                     | Xiao, 2012      |
| NH₃           | 0.99| ih          | 0.16                  | br+(3/4)bo-3/4 = 0.20                     | Xiao, 2012      |
| MMH           | 0.85| ih          | -0.045                | br+(3/4)bo-3/4 = -0.043                   | Xu, 2012        |
| Nerve gases   | 0.7 | ih         | -0.18                 | br+(3/4)bo-3/4 = -0.16                    | Tan, 2012       |
| DMH           | 0.7 | ih          | -0.084                | br+(3/4)bo-3/4 = -0.16                    | Goh, 2012       |
| H₂S, HCN, CO  | 1.0 | ih          | 0.081                 | br+(3/4)bo-3/4 = 0.07                     | Mak, 2012       |

MMH, Monomethylhydrazine; DMH, Dimethylhadrazine. Ip, intraperitoneal; ig, intragastric; ih, inhalation; iv, intravenous.
when advanced statistical method was employed. The same data sets were re-analyzed in the hope to explain the variance observed with the TOD-W^b model.

However, it is clear that once the toxicant’s target organ is ascertained, through toxicological and pathological investigation, the value of exponent b in the TOD-W^b model can be a priori determined from the parameter values bi, bm, bo, and br from literature when the mode of application (forced vs. *ad libitum*) and respective entry-route is known. Taking advantage of the model structure, animal-to-human route-to-route and chemical-to-chemical extrapolation can be carried out with the limited measured animal toxicity data. It is believed that the model can also be applied to non-mammal species as well.

The TOD-W^b model is tested with some available toxicity data from literature. So far, the study had indicated that TOD-W^b model is able to explain the constituent factors which the constant exponent (W^b) model is unable to reflect. The ability of TOD-W^b model to explain these constituent factors would enable better understanding of the influence and impact of the toxicant’s intake mode (bi), transport route (br), target organ mass (bo) and target organ metabolism (bm) without the intensity of PBPK model; serving as a meso-scale model that lie in between the macro-scale constant exponent (W^b) and the micro-scale PBPK models.

Conclusion

From datasets of cancer drugs and anesthetics, and nipradiol that target the respiratory system, the br values determined for intragastric (ig), intraperitoneal (ip), intravenous (iv) and subcutaneous (sc) injections are 0.15, 0.26, 0.03, and 0.61, respectively; from HF mouth breathing data, the br value is 0.07 for pulmonary absorption through inhalation (ih); and from data of actinomycin D that target bone marrow through the ip-route, the bo value is 0.53. The model is tested with the parameter values obtained from literature; validating the a priori values determined in this paper with the empirical values measured. For ip-administration of OMPA and parathion, the a priori [3/4(bo) - 1] value and empirical value are -0.475 and -0.48; for nine alkylating agents, the values are -0.60 and -0.61; for ig-administration of NaCN, the [br + 3/4(bo) - 1] and empirical values are -0.1 and -0.092, respectively. The analysis of toxic gas inhalation data in student projects are also summarized herein. Consequently, values of these parameters can also be estimated by fitting known toxicity data to the TOD-W^b model.

Generally, the TOD-W^b model has been tested and validated successfully to toxicity data of a single chemical administered through different routes as well as group of chemicals of the same family having the same target organ, including a set of bird toxicity data. It was believed that this TOD-W^b model is an improvement over the traditional constant exponent model as it agrees better with measured toxicity data and requires less computation resources as compared to the micro-scale PBPK model. The variable exponent, b = br + (bo)(bm) - bi, takes into account the influence of the intake-mode (bi), transport-route (br), target organ mass (bo), and the metabolism at the target organ (bm).

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

REFERENCES

Adolph EF. (1949). Quantitative relations in the physiological constitutions of mammals. Science 109:579-585.

Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V, Magrini U. (1985). Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol. Appl. Pharmacol. 79:412-422.

Brody S (1945). Bioenergetics and growth, with special reference to the efficiency complex in domestic animals. New York: Reinhold.

Burzala-Kowalczyk L, Jongblond G (2011). Allometric scaling: analysis of LD50 data. Risk Anal. 31:523-532.

Crawford JD, Terry ME, Rourke GM (1950). Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 5:783-790.

DuBois KP, Doull J, Coon JM (1950). Studies on the toxicity and pharmacological action of octamethyl pyrophosphoramide (OMPA;PESTOX III). J. Pharmacol. Exp. Ther. 99(3):376-393.

DuBois KP, Doull J, Salerno PR, Coon JM (1949). Studies on the toxicity and mechanism of action of p-nitrophenyl diethyl thionophosphate (Parathion). J. Pharmacol. Exp. Ther. 95(1):79-91.

Feldman HA, Mcmahon TA (1983). The 3/4 mass exponent for energy metabolism is not a statistical artifact. Respir. Physiol. 52:149-163.

Freireich EJ, Gehan EA, Ralll DF, Schmidt LH, Skipper HE (1966). Quantitative comparison of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50(4):219-244.

Gerlowski LE, Jain RK (1983). Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72(10):1103-1127.

Goh KP (2012). Quantitative risk assessment: Derivation of the human probit expression for the acute intoxication of dimethylhydrazine through inhalation and the scaling of animal toxicity to equivalent human exposures. Bachelor of Engineering Dissertation. Department of Chemical and Biomolecular Engineering, National University of Singapore.

Guyton AC (1947). Analysis of Respiratory Patterns in Laboratory Animals. Am. J. Physiol. 150:78-83.

Guyton AC (1947). Measurement of the Respiratory Volumes of Laboratory Animals. Am. J. Physiol. 150:70-77.

Hart DCA, Gumej J, McCoy C (2002). Project PN0908: Methods for Estimating Daily Food intake of Wild Birds and Mammals. Central Science Laboratory, Final Report for the Department for Environment, Food and Rural Affairs, United Kingdom.

Jadhav K, Gambhire M, Shaikh I, Kadam V, Pisal S (2007). Nasal Drug Delivery System-Factors Affecting and Applications. Curr. Drug Ther. 2:27-38.

Klager M (1947). Body size and metabolic rate. Physiol. Rev. 27(4):511-541.

Lim GT (2012). Allometric Scaling of HF and HCl Toxicity to Humans from Animal Data. Bachelor of Engineering Dissertation. Department of Chemical and Biomolecular Engineering, National University of Singapore.

Lindstedt SL, Calder WA II (1981). Body size, physiological time, and longevity of homeothermic animals. Q. Rev. Biol. 56:1-16.
Mak YM (2012). Derivation of Probit Equation for Quantitative Risk Analysis from Animal Toxicity Data: Gases and Vapours Causing Hypoxia. Bachelor of Engineering Dissertation. Department of Chemical.

McManus T (1973). Size and shape in biology. Science 179:1201-1204.

Mineau P, Collins BT, Baril A (1996). On the use of scaling factors to improve interspecies extrapolation of acute toxicity in birds. Regul. Toxicol. Pharmacol. 24:24-29.

Mirsalis J, Schindler-Horvat J, Hill J, Tomaszewski J, Donohue S, Tyson C (1999). Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother. Pharmacol. 44:395-402.

Nakano S, Yamashita K, Kirihara Y, Kumorita M, Morita K (1984). Acute toxicity study of 1,3,3,5,5-pentamethylidino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide (a new antitumor agent with an inorganic ring) in mice, rats and dogs. J. Appl. Toxicol. 4(1):1-7.

Okudo M, Tsuruta T, Nishigaki K, Ohta T, Kobayashi F (1985). Acute toxicity study of nipradilol and metabolite. Pharmacometrics 29:725-731.

Philips FS, Schwartz HS, Sternberg SS, Tan CTC (1960). The toxicity of actinomycin. Ann. NY Acad. Sci. 89:348-360.

Philips FS, Thiersch JB (1950). The nitrogen mustard-like actions 2,4,6-tris(ethylenimino)-s-triazine and others bis(ethylenimines). J. Pharmacol. Exp. Ther. 100:398-407.

Prenkel D (1958). The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18:853-856.

Rhomberg LR, Wolff SK (1998). Empirical scaling of single oral lethal doses across mammalian species based on large database. Risk Anal. 18:741-753.

Sato A, Nakajima T (1978). Differences following skin or inhalation exposure in the absorption and excretion kinetics of trichloroethylene and toluene. Br. J. Ind. Med. 35:43-49.

Schein PS, Davis RD, Carter S, Newman J, Schein DR, Rall DP (1970). The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11:3-40.

Stahl WR (1967). Scaling of respiratory variables in mammals. J. Appl. Physiol. 22:435-460.

Tan JB (2012). Meta-analysis of existing animal toxicity data for nerve agents to determine constants of the animal and human probit equation, human LC50 estimates and allometric retention factor through allometric modeling. Bachelor of Engineering Dissertation. Department of Chemical and Biomolecular Engineering, National University of Singapore.

Travis CC, White RK (1988). Interspecific scaling of toxicity data. Risk Anal. 8:119-126.

Wiemeyer SN, Hill EF, Carpenter JW, Krynitsky AJ (1986). Acute oral toxicity of sodium cyanide in birds. J. Wildl. Dis. 22(4):538-546.

Xiao XH (2012). Derivation of Probit Equation for Quantitative Risk Analysis from Animal Toxicity Data: Irritant Gas and Vapours. Bachelor of Engineering Dissertation. Department of Chemical and Biomolecular Engineering, National University of Singapore.

Xu B (2012). Derivation of Probit Equation for Quantitative Risk Analysis from Animal Toxicity Data: Monomethyl Hydrazine. Bachelor of Engineering Dissertation. National University of Singapore and Biomolecular Engineering, National University of Singapore.